Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/23870| Title: | Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. | Austin Authors: | Lewis, Katharine L;Chin, Collin K;Manos, Kate ;Casey, John;Hamad, Nada;Crawford, Julie;Ho, Shir-Jing;Issa, Samar;Grigg, Andrew P ;Wood, Peter;Gandhi, Maher K;Do, Bryan;Nastoupil, Loretta;Hawkes, Eliza A ;Cheah, Chan Y | Affiliation: | Department of Haematology, Middlemore Hospital, Auckland, New Zealand Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia Medical School, University of Western Australia, Nedlands, WA, Australia Linear Clinical Research, Nedlands, WA, Australia Clinical Haematology Department of Haematology, The Townsville Hospital, Townsville, QLD, Australia Department of Haematology, St Vincent's Hospital, UNSW, Sydney, NSW, Australia Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX, USA University of Melbourne, Melbourne, VIC, Australia Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia Department of Haematology, St George Hospital, Sydney, NSW, Australia Department of Haematology, Eastern Health, Box Hill, VIC, Australia Department of Haematology, Pathwest Laboratory Medicine, Perth, WA, Australia |
Issue Date: | Mar-2021 | Date: | 2020-07-16 | Publication information: | British Journal of Haematology 2020; 192(6): 1049-1053 | Abstract: | Primary and secondary central nervous system lymphomas (PCNSL/SCNSL) are aggressive rare malignancies with dismal outcomes. Encouraging data have emerged from Phase I/II clinical trials treating relapsed/refractory PCNSL/SCNSL with ibrutinib. We analysed 33 patients who received ibrutinib, alone or with other therapies, for PCNSL (n = 9) or SCNSL (n = 24). The objective response rate was 58% (complete response 55%). The median progression-free survival and overall survival for patients with PCNSL were both 3·1 months; for SCNSL, 10·2 and 11·5 months respectively. Only one invasive fungal infection was observed, despite concurrent or recent use of dexamethasone 8-16 mg daily in 14 patients (42%). Ibrutinib has encouraging activity in these aggressive malignancies. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/23870 | DOI: | 10.1111/bjh.16946 | ORCID: | 0000-0003-0549-5877 0000-0001-6880-2876 0000-0001-7929-1450 0000-0001-5743-3171 0000-0003-1000-5393 0000-0002-2094-3191 0000-0001-7988-1565 |
Journal: | British Journal of Haematology | PubMed URL: | 32677095 | Type: | Journal Article | Subjects: | BTK inhibitor central nervous system ibrutinib lymphoma novel |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.